The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Chpmpc     4-amino-1-[[(5S)-2-hydroxy-2- oxo-1,4-dioxa...

Synonyms: cCDV, Cyclic-hpmpc, CHEMBL392630, AC1L3VEZ, LS-135842, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Cyclic-hpmpc


High impact information on Cyclic-hpmpc


Biological context of Cyclic-hpmpc

  • Treatment of SV40- and adenovirus-transformed cells with ANPs resulted in the inhibition of cell proliferation as a function of time, similar to that observed with HPV-positive cells, HPMPC and cHPMPC being the most potent antiproliferative agents [7].
  • Cidofovir accounted for 2 to 12% of the total plasma AUC for butyl-, cyclohexyl- and phenethyl-salicylyl esters of cyclic HPMPC [8].

Anatomical context of Cyclic-hpmpc


Associations of Cyclic-hpmpc with other chemical compounds


Analytical, diagnostic and therapeutic context of Cyclic-hpmpc

  • The maximum concentrations of cyclic HPMPC in serum were 0.036 +/- 0.021 and 0.082 +/- 0.038 microgram/ml after the oral administration of doses of 1.5 and 3.0 mg/kg, respectively [2].


  1. Influence of intravitreal injections of HPMPC and related nucleoside analogues on intraocular pressure in guinea pig eyes. Banker, A.S., De Clercq, E., Taskintuna, I., Keefe, K.S., Bergeron-Lynn, G., Freeman, W.R. Invest. Ophthalmol. Vis. Sci. (1998) [Pubmed]
  2. Clinical pharmacokinetics of 1-[((S)-2-hydroxy-2-oxo-1,4,2-dioxaphosphorinan-5-yl)methyl]cytosine in human immunodeficiency virus-infected patients. Cundy, K.C., Barditch-Crovo, P., Petty, B.G., Ruby, A., Redpath, M., Jaffe, H.S., Lietman, P.S. Antimicrob. Agents Chemother. (1999) [Pubmed]
  3. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice. Smee, D.F., Bailey, K.W., Sidwell, R.W. Chemotherapy. (2003) [Pubmed]
  4. Pharmacokinetics, bioavailability, metabolism, and tissue distribution of cidofovir (HPMPC) and cyclic HPMPC in rats. Cundy, K.C., Bidgood, A.M., Lynch, G., Shaw, J.P., Griffin, L., Lee, W.A. Drug Metab. Dispos. (1996) [Pubmed]
  5. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Baker, R.O., Bray, M., Huggins, J.W. Antiviral Res. (2003) [Pubmed]
  6. An animal model of neonatal cytomegalovirus infection. Bravo, F.J., Bourne, N., Schleiss, M.R., Bernstein, D.I. Antiviral Res. (2003) [Pubmed]
  7. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Andrei, G., Snoeck, R., Piette, J., Delvenne, P., De Clercq, E. Oncol. Res. (1998) [Pubmed]
  8. Pharmacokinetics of salicylate ester prodrugs of cyclic HPMPC in dogs. Oliyai, R., Arimilli, M.N., Jones, R.J., Lee, W.A. Nucleosides Nucleotides Nucleic Acids (2001) [Pubmed]
  9. Cyclic HPMPC is safe and effective against systemic guinea pig cytomegalovirus infection in immune compromised animals. Bourne, N., Bravo, F.J., Bernstein, D.I. Antiviral Res. (2000) [Pubmed]
  10. Therapeutic developments in cytomegalovirus retinitis. Hoffman, V.F., Skiest, D.J. Expert opinion on investigational drugs. (2000) [Pubmed]
WikiGenes - Universities